Thyroid function and age-related macular degeneration: a prospective population-based cohort study - the Rotterdam Study

Table 3 Sensitivity analyses excluding participants with thyroid medication or thyroid disease at baseline

Incident AMD versus no AMD	AMD N	Total N	HR (95% CI), model 1	HR (95% CI), model 2	HR (95% CI), model 3
Excluded thyroid medication
Free T4	752	5,225	1.03 (1.01-1.06)	1.03 (1.01-1.06)	1.03 (1.01-1.06)
TSH, mIU/L	778	5,417	0.99 (0.91-1.08)	1.00 (0.92-1.09)	1.00 (0.91-1.09)
Excluding baseline thyroid disease^b
Free T4	751	5,237	1.04 (1.01-1.08)	1.04 (1.01-1.07)	1.04 (1.01-1.08)
TSH, mIU/L	764	5,300	0.98 (0.89-1.07)	0.98 (0.89-1.07)	0.97 (0.89-1.07)

^a155 participants had thyroid medication (thyroid hormone use) at baseline.
^b272 participants had self-reported thyroid disease at baseline.
Model 1: Adjusted for sex and age. Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, BMI. Model 3: Model 2 + thyroid peroxidase antibodies positivity.
Abbreviations: BMI body mass index, CI confidence interval, FT4 free thyroxine, HR hazard ratio, TSH thyroid-stimulating hormone.

ISSN: 1741-7015